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Osteopontin (OPN; also known as ETA1 and encoded by SPP1) has been recognized as a T-bet-dependent pro-inflammatory cytokine that is produced by activated T helper 1 (T H 1) cells. In dendritic cells (DCs), OPNdependent ligation of αvβ3 integrin induces the expression of interleukin-12 (IL-12), whereas engagement of CD44 by OPN inhibits the expression of IL-10 (refs 1,2). The interactions of OPN with CD44 and αvβ3 integrin also promote the chemotactic migration of DCs and Langerhans cells 3 . Early studies that examined the contribution of OPN to immune responses focused almost exclusively on the activities of the secreted isoform of OPN (sOPN). More recently, studies have revealed that antigen-presenting cells (APCs), including macrophages and DCs, also express an intracellular form of OPN (iOPN), which regulates cell motility, cell division and cytokine expression [4] [5] [6] [7] [8] . Molecular analysis of the expression of the Opn gene by DCs has shown that alternative translation of a single species of Opn mRNA generates two protein isoforms (sOPN and iOPN) 8 that regulate the development of T H -cell subsets 1, 2, [9] [10] [11] . In this Opinion article, we propose that the regulation of the T H 1-and T H 17-cell responses through the differential expression of sOPN and iOPN by immune cells determines the type and intensity of adaptive immune responses to foreign and self antigens.
OPN and antimicrobial responses
The contribution of OPN to protective immunity against microbial infection was first suggested by findings that the Opn gene mapped to a locus (Ric) on mouse chromosome 5 that confers resistance to infection by Rickettsia tsutsugamushi, an obligate intracellular bacterium that causes human scrub typhus 12, 13 . Subsequent studies suggested that OPN expression also contributes to protective immunity against several additional intracellular pathogens, including viruses, bacteria and protozoa [14] [15] [16] [17] [18] [19] . Further evidence of the contribution of OPN to the protection against intra cellular pathogens came from a study on OPNdeficient mice, which were more susceptible to infection with Mycobacterium bovis than OPN-sufficient mice 15 . Although the expression of sOPN may also promote antimicrobial immunity through the suppression of the anti-inflammatory cytokine IL-10 . Moreover, analysis of plasma from patients with tuberculosis revealed that high levels of sOPN correlated with increased levels of IL-12 (refs 17,18) , perhaps reflecting an interaction between sOPN and its receptor αvβ3 integrin, which can upregulate IL-12 secretion by APCs 14 . OPN expression (detected by immunohistochemistry) in patients with tuberculosis was also associated with efficient granuloma formation and inversely correlated with mycobacterial dissemination and disease mortality 16 . Analysis of OPN-deficient mice suggested that this protein also contributes to protection against other intracellular pathogens, including rotavirus 19 , herpes simplex virus type 1 (refs 1,9) , Listeria monocyto genes 1 and Plasmodium falciparum 10 . Although protection against intracellular pathogens has generally been attributed to the expression of sOPN, protection against some of these microorganisms may also be the result of iOPN expression. Several studies using immunohistochemistry or flow cytometry showed that OPN was present in pathogen-infected cells 10, 16 . However, additional investigation is required to determine whether these studies reflect the presence of iOPN, sOPN or both isoforms.
The protective role of OPN against infection does not extend to all types of pathogen. For example, OPN deficiency does not attenuate resistance to some viruses, including influenza virus 21 , or to the extracellular bacterium Borrelia burgdorferi in mice 22 . In the study examining the effect of OPN deficiency on the protection against viral infections 21 , OPN-independent production of antiviral cytokines, including interferon-α (IFNα), could have bypassed the need for OPN-dependent protection 23 . In the case of B. burgdorferi infection 22 , the pathogen inocula that were used in this study might have been insufficient to induce OPN-dependent protection, as suppression of IL-10 by OPN, which results in enhanced resistance to B. burgdorferi 24 , may require higher titres of this bacterium.
In addition to sOPN-dependent induction of the pro-inflammatory cytokine IL-12 
OPN and autoimmune diseases
The relationship between OPN expression and autoimmune disease was first suggested by findings showing that overexpression of Opn mRNA positively correlated with the onset and increased severity of systemic lupus erythematosus (SLE) in mice 25 . In addition, Opn allele-specific effects were observed for development of the SLE-like disease in susceptible mouse strains: the presence of Opn MAL predisposes animals to lupus-associated nephritis, whereas the presence of Opn C3H does not 26 . High levels of OPN have also been reported in patients with autoimmune lymphoproliferative syndrome 27 , and polymorphisms of the human OPN locus have been linked to susceptibility to SLE 28, 29 . Furthermore, OPN is thought to contribute to the pathogenesis of some forms of arthritis, as OPN-deficient mice are protected from joint destruction that occurs during collagen-antibody-induced arthritis 30 . In addition, the pathogenesis of collagen-antibody-induced arthritis and collagen-induced arthritis can be ameliorated by binding of the OPN antibody to a cryptic epitope that is exposed on sOPN after it is cleaved by thrombin 31, 32 . by contrast, OPN-deficient mice were not resistant to arthritis in other studies that used a different model of collagen-induced arthritis or in the K/bxN arthritis models 33, 34 . Although the reason for these discrepant results is currently unknown, these findings emphasize the distinct pathogenic pathways that are responsible for the development of arthritis in different mouse models.
OPN has been implicated in the development of autoimmune diseases that are mediated by T H 1 or T H 17 cells. However, sOPN has also been implicated in allergic airway diseases, which are mediated by T H 2 cells 35 . Inhibition of pDC migration to draining lymph nodes by sOPN resulted in enhanced pro-inflammatory responses and airway hypersensitivity during primary systemic sensitization. In addition, sOPN-dependent inhibition of the migration of cDCs to pulmonary lymph nodes following allergen challenge suppressed the pulmonary allergic response 35 . Thus, sOPN regulates T H 2-type responses in airway hypersensitivity through temporal inhibition of either pDC or cDC migration. How sOPN achieves temporally distinct inhibition of pDC and cDC migration is not understood. It is possible that sOPN-dependent retention of recently arrived cDCs in draining lymph nodes through the suppression of CC-chemokine receptor 5 (CCR5) and CCR7 expression may prevent excessive homing of activated cDCs to inflamed tissues and draining lymph nodes 36 . Further studies are necessary to fully delineate the role of sOPN (and iOPN) in T H 2-type responses.
intracellular OPN Translation of sOPN is initiated from the AuG codon that is located at the 5′-end of the Opn signal sequence, which targets fulllength nascent sOPN to secretory vesicles 8 ( fIG. 1) . Evidence for an intracellular form of OPN (iOPN) that localizes outside of secretory vesicles was initially inferred from its perinuclear distribution in rat calvarial cells 4 . iOPN is a shorter isoform of sOPN that is produced by alternative translation, which is initiated downstream of the conventional AuG start site and therefore lacks the signal sequence at the amino terminus. Expression of the two isoforms differs depending on cell type: DCs express high levels of iOPN but low levels of sOPN, whereas the reverse is true of activated T cells 2 . It is possible that cell-type-specific factors may regulate the alternative translation of Opn mRNA.
Analysis of the subcellular localization of iOPN in DCs by confocal microscopy and gradient separation has confirmed that it is localized in the cytoplasm and dendrites 8 , but not in the Golgi apparatus. This expression pattern reflects the direct entry of nascent iOPN protein into the cytoplasm following its synthesis 8 . The functional properties of iOPN suggest that it may function as an adaptor protein rather than as a catalytic molecule. It colocalizes with myeloid differentiation primary-response gene 88 (MyD88) and Toll-like receptor 9 (TLR9) in DCs, and with ezrin (a component of the ezrin-radixinmoesin complex), polo-like kinase 1 and the cytoplasmic domain of CD44 in other cell types [5] [6] [7] 9, 37 . iOPN is a member of the SIbLING (small integrin-binding ligand N-linked glycoproteins) family, the members of which display extended folding in solution and have structural features that enable them to interact with multiple binding partners and to facilitate the organization of specialized macromolecular clusters 38 .
iOPN in pDCs and T H 1-cell responses.
Although all nucleated cells can produce type I IFNs, pDCs are specialized cells that rapidly secrete high levels of type I IFNs following viral stimulation. binding of type I IFNs to the type I IFN receptor (IFNAR) 39 upregulates IFNγ production; therefore, this pathway favours the induction and maintenance of T H 1-cell responses [40] [41] [42] .
Nature Reviews | Immunology Engagement of TLR9 results in T-betdependent expression of iOPN in pDCs 9 . Association of nascent iOPN with MyD88 results in the activation of the transcription factor IFN-regulatory factor 7 (IRF7) and induction of Ifna expression 9 . Although TLR9-dependent activation of MyD88 can also activate the transcription factor nuclear factor-κb (NF-κb) and induce the expression of pro-inflammatory cytokines, including IL-6 and tumour-necrosis factor (TNF), iOPN has been shown to selectively couple TLR9 activation with that of IRF7 instead of NF-κb 9 . Some of the functional consequences of this iOPN-dependent pathway for IFNα production in pDCs have been delineated. iOPN expression by pDCs is essential for IFNα-dependent antigen cross-presentation to CD8 + T cells, resistance to infection by herpes simplex virus type 1 and induction of natural-killer cell cytotoxicity that protects mice from the lethal effects of b16 melanoma 9 . These findings are consistent with the view that iOPN expression by pDCs is essential for IFNα-dependent immunity and T H 1-cell responses in vivo.
iOPN in cDCs and T H 17-cell responses. T H 1 and T H 2 cells enhance the clearance of intracellular bacteria and viruses or parasites, respectively. A recently defined third subset of T H cells that produce IL-17 -termed T H 17 cells -can protect the host from infection
by extracellular bacteria and fungi, including clinically important pathogens such as B. burgdorferi and Candida albicans 43, 44 . However, IL-17 can also promote tissue damage, and uncontrolled T H 17-cell responses are thought to contribute to several human autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and SLE [45] [46] [47] [48] [49] [50] . Recent studies have shown that iOPN expression by cDCs has a key role in promoting T H 17-cell responses. iOPN suppresses the expression of IL-27, which is known to inhibit the development of T H 17 cells 11 . In addition, OPN-deficient cDCs secrete high levels of IL-27 and therefore attenuate the T H 17-cell response. This suggests that iOPN releases the 'brake' on the T H 17-cell responses by suppressing IL-27 (refs 51,52) . whether sOPN expression by activated T cells also participates in the generation or maintenance of the T H 17-cell response is currently being investigated.
Furthermore, engagement of IFNAR has been shown to suppress the expression of iOPN, which leads to enhanced secretion of IL-27 and, consequently, to attenuated T H 17-cell responses 11, 53 . In addition, engagement of IFNAR following viral infection results in an IL-27-dependent blockade of T H 17-cell responses 11 . This effect may prevent unwanted or excessive inflammatory responses during viral infection, without compromising the protective antiviral immunity that is mediated by pDCs and T H 1 cells. T H 17-cell responses may be further inhibited by the increased iOPN-dependent secretion of type I IFNs by pDCs following TLR7 or TLR9 activation by viral RNA or DNA, which would activate IFNAR on the surface of cDCs (fIG. 2) . Therefore, this interaction between the two main DC subsets may regulate the level of activation of T H -cell subsets.
OPN in the central nervous system
The identification of a potential role for OPN in the pathogenesis of multiple sclerosis came from findings that plaques from the brain and spinal cords of rats with experimental autoimmune encephalomyelitis (EAE) contained high levels of Opn transcripts 54 and that OPN-deficient mice showed decreased development of the disease 54, 55 . The initial concern that other genes linked to the Opn locus might be responsible for the second finding proved to be unfounded 56 , as administration of recombinant OPN to wild-type mice exacerbated disease 57 , and the attenuated phenotype that was observed in OPNdeficient mice was still apparent after 16 generations of backcrossing 2 . both sOPN and iOPN have been shown to regulate EAE development. T-cell-derived sOPN can inhibit apoptosis of pathogenic T cells, thereby sustaining T-cell pathogenicity during the relapse and progression of EAE 57 . In addition, the expression of iOPN by APCs, rather than T cells, regulates the onset of EAE 11 and the generation of proinflammatory T H 17 cells, as determined by immunization with antigen-pulsed DCs that differ in their expression of iOPN 11 . These findings suggest that iOPN expression by DCs exacerbates EAE development by promoting the T H 17-cell response, whereas sOPN may sustain disease by dampening apoptosis of pathogenic T cells (fIG. 3) .
Future prospects
Although IFNβ therapy is currently the leading treatment for multiple sclerosis 58 , the underlying mechanism of its effect on disease progression is not understood. Recent studies 11, 53 suggest that suppression of the T H 17-cell response by the IFNARdependent pathway described above (fIG. 2) could account for its ameliorative effects Nature Reviews | Immunology . Moreover, engagement of IFNAR expressed by myeloid cells that reside in the central nervous system can inhibit cytokine and chemokine production and diminish phagocytosis of myelin by these cells 39 .
These data indicate that it may be possible to produce new IFNAR agonists that more efficiently activate the iOPN-IL-27 pathway and thus diminish the T H 17-cell response without activating antiviral pathways that may lead to IFNβ-related side effects. This approach has already been initiated using a 'mutate and screen' method 59 , which has successfully isolated mutant IFNα molecules that induce increased antiviral and T H 1-cell responses without concomitant increases in anti-proliferative potential 60 . Although the study did not evaluate the effect of these mutant IFNα molecules on T H 17-cell responses, it is plausible that the responses may be altered by interactions between IFNAR and IFNα ligands that contain appropriate mutations. Increased suppression of iOPN by IFNAR agonists may also serve as an important marker for the evaluation of new treatments for multiple sclerosis.
Research into the contributions of OPN to the regulation of immune responses has focused primarily on the cytokine-like activities of sOPN that is produced by T cells. However, recent studies have uncovered a new isoform of OPN that is expressed as an intracellular protein in DCs and macrophages. Analysis of the contribution of iOPN expression to the immunological activities of DCs has suggested a key role for this protein in DC-dependent regulation of T H 1-and T H 17-cell responses. In view of recent studies suggesting that both T H 1 and T H 17 cells are involved in the pathogenesis of multiple sclerosis and EAE (reviewed in ref. 61) , the ability of OPN isoforms to regulate T H 1-and T H 17-cell responses may prove to be relevant to new types of treatment for clinically distinct subsets of multiple sclerosis. The task ahead is to further define the individual and combined contribution of the two OPN isoforms to the development of the different T H -cell subsets in the context of protective immunity and autoimmune disease. This can be achieved, in part, by analysing cells or animals that are genetically engineered to express sOPN or iOPN in different cell types and by the translation of these findings to new approaches that regulate the expression of the two OPN isoforms in different diseases. 
